"Institut de Cancérologie Lucien Neuwirth Service pharmacie-Essais cliniques"
Welcome,         Profile    Billing    Logout  
 3 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jacquin, Jean-Philippe
PELICAN, NCT03515798 / 2016-001868-11: Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

Checkmark PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.
Checkmark A prospective, multicentre, open-label, randomized phase II study of PEmbroLizumab in combination with neo-adjuvant (F)EC-paclitaxel regimen in HER2-negative Inflammatory breast CANcer
Recruiting
2
81
Europe
Pembrolizumab Injection, MK3475, neoadjuvant EC-paclitaxel chemotherapy, Epirubicine, Cyclophosphamide, Paclitaxel
Institut Paoli-Calmettes, MSD France, Oncodistinct
Inflammatory Breast Cancer
12/20
04/25
PROFILER, NCT01774409: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer

Checkmark Feasibility of an explainable AI-based therapeutic recommendation-tool utilizing tumor gene expression profiles in advanced and refractory solid tumors.
Checkmark Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Checkmark Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Checkmark Utility of a general molecular screening program in patients with GU malignancies: The ProfiLER trial experience.
Checkmark Utility of a general molecular screening program in patients with GU malignancies: The ProfiLER trial experience.
More
Recruiting
N/A
10000
Europe
Blood and tumor samples
Centre Leon Berard
Neoplasms
07/23
07/23
FAVRE, Pauline
No trials found

Download Options